Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2012
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 19 Jul 2011 New trial record